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Abstract
The class of human genetic kidney diseases is extremely broad and heterogeneous. Accordingly, the range of
associated disease phenotypes is highly variable. Many children and adults affected by inherited kidney disease
will progress to ESKD at some point in life. Extensive research has been performed on various different disease
models to investigate the underlying causes of genetic kidney disease and to identify disease mechanisms that are
amenable to therapy. We review some of the research highlights that, by modeling inherited kidney disease,
contributed to a better understanding of the underlying pathomechanisms, leading to the identification of novel
genetic causes, new therapeutic targets, and to the development of new treatments. We also discuss how the
implementation of more efficient genome-editing techniques and tissue-culture methods for kidney research is
providinguswithpersonalizedmodels for aprecision-medicineapproach that takes intoaccount the specificitiesof
the patient and the underlying disease. We focus on the most commonmodel systems used in kidney research and
discuss how, according to their specific features, they can differentially contribute to biomedical research.
Unfortunately, nodefinitive treatmentexists formost inheritedkidneydisorders,warranting furtherexploitationof
the existing disease models, as well as the implementation of novel, complex, human patient–specific models to
deliver research breakthroughs.
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Introduction
There are .150 human genetic kidney diseases that
may affect kidney development or kidney tissue
maintenance, leading to glomerular, tubular, and
structural defects (1). The range of disease pheno-
types associated with genetic diseases is huge. There
are groups of kidney diseases where the phenotypes
are largely kidney limited, such as autosomal-dominant
tubulointerstitial kidney disease secondary to uro-
modulin (UMOD) mutations, where the molecular
defect is restricted to the cells of the thick ascending
limb of the loop of Henle (2). Glomerulopathies,
such as inherited forms of nephrotic syndrome with
podocyte-specific defects (3) and tubulopathies (4)
such as Gitelman syndrome and nephrogenic diabetes
insipidus, where encoded proteins are expressed in a
specific tubular segment, would also be in this group.
Other groups of inherited disorders are labeled as
kidney disease but actually display phenotypes in
multiple organs, such as autosomal dominant poly-
cystic kidney disease (ADPKD)where cystsmay be seen
in organs aside from the kidney, as well as leading to
berry aneurysms and valvular heart lesions (5,6). There
are other examples of kidney genetic diseases with extra
kidney manifestations, including Alport syndrome and
related collagenopathies, which have prominent deaf-
ness and eye phenotypes. Inherited lysosomal storage
disorders such as Fabry disease and disorders such as
cystinosis, tuberous sclerosis, and von Hippel–Lindau
syndrome have prominent kidney phenotypes but
are really systemic diseases. Developmental causes
of kidney disease such as mutations in transcription
factors, for example HNF1b, have multisystem
and highly variable phenotypes. Finally, there are
ciliopathy disorders, such as nephronophthisis, which
have dramatic kidney phenotypes but may be associ-
ated with multisystem phenotypes consistent with the
underlying defect in primary cilia (see Glossary).
Human genetic diseases of the kidney may be
grouped in terms of frequency. ADPKD remains the
most common inherited cause of kidney disease
leading to end stage kidney failure and research has
often been championed in the field of cystic kidney
disease and then subsequently pursued in other
disease groups.
Extensive research has been conducted on disease
models for inherited kidney disease to identify aber-
rant pathways and novel therapeutic targets (Figure 1).
These models have also been used for drug screening
and testing (Figure 1). Moreover, animal and cellular
models represent a useful platform to validate the
pathogenicity of novel mutations and variants of
unknown significance, and to identify novel genetic
causes of inherited kidney disease with forward and
reverse genetic studies (Figure 1). Gene editing systems
such as clustered regularly interspaced short palindromic
repeat (CRISPR)/Cas now allow the precise introduc-
tion of the candidate mutation, allowing a fast and
easy generation of humanized and patient-specific
disease models, paving the way for precision-medicine
approaches (Figure 1).
This review will discuss the features that charac-
terize the different model systems most commonly
used in kidney research—namely Chlamydomonas
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reinhardtii, Caenorhabditis elegans, Drosophila melanogaster (fruit
fly), Danio rerio (zebrafish), Mus musculus (mouse), and
mammalian cell cultures (Table 1)—and how they have
differently contributed to the study of inherited kidney
disorders in the context of the ever-evolving landscape of
tools available for kidney genetics studies (Table 2). This
information can prove useful in making the decision of
which model should be used for future research, depend-
ing on the type of study and the features of each model
(Figure 2). We also present some of the research high-
lights that, through the use of animal and cellular disease
models, demonstrate how preclinical model systems have
significantly contributed to the understanding of human
inherited kidney diseases.
Seminal Studies in C. reinhardtii and C. elegans: the
Golden Era of the Primary Cilium
Traditionally, until the early 2000s, nephrology research
on animal models mainly involved the study of sponta-
neously arisen rodent models such as the cystic kidney
disease cpk (7), bpk (8), and jck (9) mouse models and the
cystic kidney PCK rat (10). These models had similarities
to clinical features of human polycystic kidney disease
(PKD) but, for several years, the underlying mutated gene
in these animals remained unidentified, which hindered any
further study on the associated pathomechanisms.
One of the greatest contributions to the understanding
of pathomechanisms of kidney disease came from studies
on two model organisms that do not possess a kidney, the
flagellated unicellular green alga C. reinhardtii and the
nematode C. elegans, which revealed for the first time a
surprising but compelling link between defects in primary
cilia and cystic kidney disease.
The first clues of a link between kidney cysts and cilia
came from the study of two C. elegans genes required for
male sensory behaviors, lov1 and pkd2, homologs of PKD1
and PKD2, the known genetic causes of ADPKD in humans.
Barr and Starnberg (11) found that lov1 and pkd2 proteins
were enriched in C. elegans sensory neuron cilia. Later
studies then confirmed ciliary localization of the human
ortholog proteins polycystin-1 and polycystin-2 in human
and mouse kidney cells (12,13).
Confirmation of the link between cilia and cystic kidney
disease came from a seminal study by Pazour et al. (14) who
showed that ift88, the Chlamydomonas homolog of the gene
mutated in the orpk (Tg737) mouse with PKD, encodes the
intraflagellar transport subunit ift88, which is necessary for
the assembly of Chlamydomonas flagella and mammalian
cilia. Following this study, cloning of the mutated gene in
the traditional spontaneous models of PKD confirmed
that the disease-causing gene encoded a ciliary-associated
protein also in the cpk mouse (15), in the bpk mouse (16,17),
in the jck mouse (18), and in the PCK rat (19).
Glossary.
Centrosome/basal body: the centrosome is a cellular structure made of two centrioles (aggregates of microtubules
arranged in a barrel-like shape). The centrosome is involved in cell division. When the cell is not dividing, a single
centriole forms the basal body, which works as a template for the formation of the primary cilium.
Forward genetics: a genetic approach that, starting from the observation of a phenotype, identifies the
associated genetic cause.
Primary cilium: an immotile, hairlike, microtubule-based cellular organelle found in many eukaryotic cells that
protrudes from the surface of the cell, where it is thought to work as a cellular antenna for stimuli sensing. Primary
cilia are made of nine doublets of microtubule filaments (910 configuration), as opposed to motile cilia that also
contain a central doublet (912 configuration). A cell possesses only one primary cilium.
Reverse genetics: a genetic approach that identifies the function of a gene of interest by studying the phenotypic
effects of alterations in the gene expression and/or sequence.
Site-directed mutagenesis: a method to generate changes in the DNA of a specific genomic sequence.
Transgene: an exogenous DNA sequence introduced in the genome of an organism.
Clustered regularly interspaced short palindromic repeat (CRISPR): works in combination with a CRISPR-
associated endonuclease (Cas protein). Engineered CRISPR/Cas constitutes a genome-editing system that binds
to a target DNA sequence complementary to a portion of a short synthetic RNA (guide RNA). Another portion of
the guide RNA mediates the binding to the Cas protein that is responsible for cutting the DNA.
GAL4-UAS: this is based on the Saccharomyces cerevisiae transcription factor GAL4, which is put under the
control of a promoter or enhancer and introduced into the genome of a Drosophila line. An effector line carries a
target gene under the control of UAS, the GAL4 binding motif. When a GAL4-driver line is crossed with the
effector line, the target gene will be expressed in the offspring.
RNA interference (RNAi): a conserved biologic process that acts on double-stranded RNA and results in its
nucleolytic degradation. This process can be leveraged by researchers to achieve sequence-specific gene silencing
by introducing into the organism short-interfering RNA (siRNA) that leads to the degradation of the targeted
RNA.
Transcription activator-like effector nucleases (TALENs): a genome-editing technique that is based on a
nuclease domain for DNA cleavage fused to a customizable DNA-binding domain.
Zinc-finger nucleases (ZFNs): these are based on customizable zinc-finger DNA-binding domains. A large
number of engineered zinc-finger arrays are fused to a nonspecific nuclease domain to cleave a target DNA
sequence. ZFNs function as dimers.
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Identification of the genetic causes of several other mono-
genic cystic kidney disorders, together with the discovery
that—in the majority of cases—the encoded proteins local-
ized to the cilium, added a growing body of evidence
confirming the association between primary cilia defects
and cystic kidney disease (20).
Due to the fact that C. elegans is easy to maintain in
culture and to genetically manipulate and that cilia are not
required for its development or viability (21), it continues to
be extensively used to investigate the ciliary functions of
kidney disease genes such as BBS1 (22), RPGRIP1L (23),
TMEM107 (24), and TTC21B (25). Discovery of the role of
these genes in ciliary assembly and/or trafficking is essen-
tial to reveal ciliary-specific protein networks and the
pathways involved in the pathogenicity of cystic kidney.
The Fly: an Insect Model for Human Glomerulopathies
D. melanogaster (fruit fly) has an excretory system
responsible for clearance of substances and maintenance
of water, salt, and pH homeostasis, which can therefore
be considered functionally homologous to the human
excretory system. The excretory system in Drosophila
consists of the Malpighian tubules (26), analogous to
kidney tubules and the nephrocytes, which correspond
to some extent to the glomeruli. Nephrocytes are specialized
cells that filtrate hemolymph (the Drosophila’s blood) and,
through their endocytic activity, regulate its composition.
There are two types of nephrocytes in the fly: the garland
nephrocytes, along the esophagus, and the pericardial
nephrocytes. Nephrocytes are surrounded by basement
membrane and are characterized by cellular protrusions
and folding of the plasmamembrane, bridged by a diaphragm
structure. This structure is very reminiscent of the mammalian
glomerular filtration system (27). Drosophila orthologs of
podocyte-specific proteins required for maintenance of the
molecular sieve in the human glomeruli, such as nephrin
and podocin, are expressed in the nephrocytes (28,29).
The conservation of several human disease genes in the fly
(30) makes it an attractive model in biomedical research and,
in the last decade, it became an established model in kidney
research, particularly in the field of podocytopathies (27) and,
more recently, of nephrolithiasis (kidney stones) (31,32).
Low maintenance costs and a fast reproductive cycle
makeDrosophila particularly suitable for large-scale screens.
Chemical and insertional mutagenesis can be applied for
forward genetic studies but the toolbox for targeted genetic
manipulation is especially rich in Drosophila.
Largely used is the GAL4-UAS system, which allows
spatially and temporally restricted expression of transgenes
(33). The use of tissue-specific enhancers within this system
allows specific targeting of nephrocytes. GAL4-UAS can
be used to achieve silencing of the gene of interest, by
combining it with RNA-interference techniques to knockdown
the gene post-transcriptionally (34) or with the CRISPR/Cas9
gene-editing system for nephrocyte-specific gene knockout
(35). Moreover, it is possible to perform rescue experiments
by expressing the wild-type or mutant orthologous human
protein in the corresponding Drosophila knockout line (36),
which can be particularly useful to verify the pathogenicity
of specific mutations.
Powerful functional studies to rapidly assess nephrocyte
filtration and endocytosis are available and consist of mon-
itoring the uptake by nephrocytes of tracers such as fluores-
cently labeled albumin or dextran ex vivo or in vivo.
The combination of all of these features makes the fly a very
powerful model for gene-discovery studies (37) and to inves-
tigate the pathomechanism of inherited glomerulopathies (35).
Applying Drosophila models to the study of inherited
forms of steroid-resistant nephrotic syndrome, Hermle et al.
(35) were able to link the pathogenesis of COQ2-associated
human nephropathy to the formation of mitochondrial
Figure 1. | Some of the most common disease models used in kidney research contribute to different aspects of our understanding of
inherited kidney disease.
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Table 1. Summary of the specificities that distinguish C. reinhardtii, C. elegans, D. melanogaster, the zebrafish, the mouse, and two- and three-dimensional cell cultures as models in kidney
research
Model Maintenance Costs
Availability of Tools for Gene
Manipulation in Reverse
Genetics
Suitability forHigh-Throughput
Studies (Drug Screens and
Forward Genetics)
Similarity to the
Human Genome Similarity to the Human Kidney
C. reinhardtii Low RNAi (gene silencing); CRISPR/
Cas9 (gene editing) has been
reported in Chlamydomonas
(112,113), butwith lowediting
efficiency
Yes. Characteristics such as
small size, low maintenance
cost, and genome haploidy
during vegetative state make
Chlamydomonas particularly
suitable for high-throughput
studies, such as mutagenesis
and small molecule screens
(114–116)
Chlamydomonas and humans
share 706 protein families
(117) and these are enriched
in cilia and centrosome/basal
body proteins (118)
The fact that theoverall structure
is well conserved between
Chlamydomonas flagellum and
human cilia makes it a good
model to study kidney
ciliopathies. Chlamydomonas
flagellum has a 912
configuration, typical of
motile cilia, as opposed to the
910 configuration of primary
cilia in the kidney tubule
C. elegans Low RNAi; ZFNs (gene editing);
TALENs (gene editing);
CRISPR/Cas9
Availability of strains with
fluorescently tagged proteins
for in vivo microscopy and
easy analysis of cilia defects
through functional tests and
by verifying the ability to
uptake lipophilic dye through
the ciliamakeC. elegans agood
model for high-throughput
screens of ciliary phenotypes
(119)
38% of C. elegans protein-coding
genes has a unique
corresponding functional
ortholog in human (120)
C. elegans has an excretory
system in part functionally
homologous to the human
urinary tract but its relevance
in kidney disease is mainly
due to its role in cilia research.
Ciliary structure is well
conserved between C. elegans
and human with many
conserved ciliary and basal
body proteins. Cilia
configuration inC. elegans is of
the 910 type, as in primary
cilia of kidney epithelial cells
D. melanogaster
(fruit fly)
Low GAL4-UAS (transgenic tool for
targeted gene expression);
RNAi; CRISPR/Cas9
Yes. Drosophila is an excellent
model for large-scale studies
due to its small size, low
maintenance costs, rapid
reproductive cycle, and the
availability of transgenic lines
for the simplified
visualization of Drosophila
excretory system
.75% of human disease genes
have aDrosophilaortholog (30)
The fly excretory system clears
unwanted substances and
maintains water, salt, and pH
homeostasis. As such, it is
functionally homologous to
the human excretory system.
Malpighian tubules
correspond to the kidney
tubules and nephrocytes to
the glomeruli
D. rerio (zebrafish) Low mRNA microinjection for
overexpression studies; MO
(gene silencing); ZFNs;
TALENs, CRISPR/Cas9
Yes. Small size and availability
of transgenic lines to visualize
the pronephros and ciliamake
it a good model for high-
throughput screens in kidney
research (41)
Approximately 70% of human
genes have at least one
functional homolog in
zebrafish (39). Zebrafish has
many duplicated genes due to
a whole-genome duplication
event inearly teleost evolution
(55)
The major difference between
the excretory system of
zebrafish and that of human is
that zebrafish does not
developametanephric kidney
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Table 1. (Continued)
Model Maintenance Costs
Availability of Tools for Gene
Manipulation in Reverse
Genetics
Suitability forHigh-Throughput
Studies (Drug Screens and
Forward Genetics)
Similarity to the
Human Genome Similarity to the Human Kidney
M. musculus
(mouse)
High In contrast to other model
systems, targeted
mutagenesis in mouse
embryonic stem cells
exploiting homologous
recombination had been
possible, although not
straightforward, well before
the advent of CRISPR/Cas
gene-editing system.
CRISPR/Cas technologies
have considerably simplified
the generation of knockout
and knockin murine models
Although it has been used in
seminal forward genetic
studies (121), due to high
maintenance costs and
relatively long reproductive
cycle, the mouse is not often
the model of choice for large
screens
Mice and humans share
approximately 70% of
protein-coding genes (122)
The macroanatomy of the
kidney is overall well
conserved between mouse
and human. Important
differences in the regulationof
master transcription factors in
nephrogenesis account for
differences such as the higher
number of nephrons in
human. A more detailed
comparison can be found in
(123)
Two-dimensional
cell culture
Low Cell cultures are extremely
amenable to genetic
manipulation. Among others,
RNAi and CRISPR/Cas9 are
probably the most commonly
used tools to achieve
knockdown and knockout/
knockin, respectively, in two-
dimensional cell cultures
Yes Depends on the species of origin.
It is possible to obtain patient-
specific cells
N/A
Three-dimensional
cell culture
For spheroid setting
generally low, higher
costs for kidney
organoids due to
employment of
growth factors to
direct differentiation
to kidney lineages
mIMCD-3 spheroids were
shown to be amenable to
RNAi approaches (124). Due
to low accessibility of the
innermost core of kidney
organoids, delivery of tools
for transient gene knockdown
or overexpression may prove
difficult. Kidney organoids
have been derived from iPSCs
knockout lines for polycystic
kidney disease genes
generatedwith CRISPR/Cas9
(103)
Yes Depends on the species of origin.
It is possible to obtain patient-
specific URECs to generate
spheroids (80) or patient-
specific iPSCs to generate
kidney organoids (106)
Spheroids: N/A
Kidney organoids: main
limitations of the model that
distinguish it from the human
kidney are reduced size and
vasculature, immaturity,
lack/underrepresentation of
certain cell types, and the
absence of a branched
collecting duct system (125)
RNAi, RNA interference; CRISPR, clustered regularly interspaced short palindromic repeat; ZFNs, zinc finger nucleases; TALENs, transcription activator-like effector nucleases; MO,
morpholino; N/A, not applicable; mIMCD-3, mouse inner medullary collecting duct cell line; iPSCs, induced pluripotent stem cells; URECs, urine-derived renal epithelial cells.
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Table 2. Summary of the strengths and limitations to guide the use of some common techniques used in kidney research
Gene Expression
Manipulation
Technique
Effect Strengths Limitations When It Should Be Used
siRNA transfection RNAi (post-transcriptional
gene silencing)
Inexpensive, rapid, and
high-throughput
The transfection of synthetic siRNA usually
leads to transient effects. Moderate risk of
off-target effects. Can lead to variable and
partial gene silencing
To perform a rapid experiment in organisms
such as Chlamydomonas, C. elegans, or
Drosophila, or in cell lines to assess the target
gene function. It is good practice to use
several siRNAs with different sequences
that target the same gene to confirm the
specificity of the observed effects
mRNA transfection/
microinjection
Gene (over)expression Inexpensive, rapid, and high
throughput
The effects of mRNA transfection/
microinjection strongly depend on the
quantity of mRNA introduced into
the organism. Careful interpretation of
the results iswarranted especiallywhen the
organism is forced to translate the
exogenousmRNAat high, nonendogenous
levels
Often used in rapid zebrafish and cell-based
experiments to assess gene function or to
perform rescue experiments (in
combination with silencing of the same
gene or of an interacting gene)
MO transfection/
microinjection
Post-transcriptional gene
silencing
High RNA affinity with superior
ability to invade RNA secondary
structure, resulting in high
targeting predictability.
Resistance to nucleases
The effects of transfection/microinjection of
MO are transient. Moderate risk of off-
target effects. Can lead to variable and
partial gene silencing
Often used in rapid zebrafish and cell-based
experiments. It is good practice to use
several MOs with different sequences that
target the same gene to confirm the
specificity of the effects observed
ZFNs Gene editing Can target virtually any sequence
in the genome
Engineering anddesign of ZFN is challenging
and time consuming. Risk of off-target
effects
Whenwanting toobtainamutant organismor
a stable cell line
TALENs Gene editing Design simplicity Risk of off-target effects Whenwanting toobtainamutant organismor
a stable cell line
CRISPR/Cas Gene editing Design simplicity and efficiency,
whichmake this technique overall
significantly less expensive and
less time consuming than other
gene editing systems
CRISPR/Cas system shares with other gene-
editing systems the risk of off-target effects.
Target sequence needs be adjacent to a
specific protospacer adjacent motif
Whenwanting toobtainamutant organismor
a stable cell line. Can also be used for rapid
gene silencing experiments without
selection of the mutated founder organism
or cell clone (e.g., to produce zebrafish
crispants or mixed mutant cell
populations). Due to its design simplicity
and efficiency, it is to be considered the
technique of choice to achieve gene editing
inmostcases.Whole-genomesequencing to
assess specificity of gene editing inamutant
organism or stable cell line, albeit
expensive, should be performed
siRNA, short interfering RNA; RNAi, RNA interference; MO, morpholino; ZFNs, zinc finger nucleases; TALENs, transcription activator-like effector nucleases; CRISPR, clustered regularly
interspaced short palindromic repeat.
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reactive oxygen species, which may be particularly delete-
rious in podocytes. The same group used a Drosophila
knockdown model to perform functional studies on
GAPVD1, a novel genetic cause of monogenic steroid-
resistant nephrotic syndrome (38).
A powerful in vivo system was recently established in
Drosophila, which consists of a transgenic line characterized
by the expression of a muscle-secreted fluorescent protein
and easily detectable GFP-labeled nephrocytes, combined
with a nephrocyte-specific driver for targeted gene knock-
down (37). The availability of such a system can be extremely
useful to screen for novel genetic causes of human glomer-
ulopathies and makes Drosophila an important contributor in
kidney research.
Zebrafish: Powerful Vertebrate Models of Kidney
Disease Devoid of a Proper Kidney
A total of 70% of human genes have at least one zebrafish
functional ortholog (39). Unlike human, zebrafish is de-
void of a metanephric kidney and only a pronephros and
subsequently a mesonephric kidney form during zebrafish
development. Another major difference between human
and zebrafish is the absence of a segment homologous to
the mammalian loop of Henle in the zebrafish nephron.
The zebrafish pronephros forms at around 24 hours post-
fertilization and consists of a pair of segmented epithelial
tubules with a fused glomerulus. The pronephros is fully
functional at 48 hours post-fertilization (40).
Characteristics such as optical transparency, rapid organo-
genesis, small size, low maintenance costs, and high fecundity
make zebrafish a useful model organism in genetic-medicine
research and make it particularly suitable for large forward
genetic and drug screens.
By screening mutagenized animals for phenotypes of
interest, forward genetic screens allow for the discovery
of previously unrecognized novel genetic causes of human
disease. Zebrafish can be randomly mutagenized by ex-
posing them to the mutagenic agent N-ethyl-N-nitrosourea
(ENU; the mating scheme to generate mutant lines is
exemplified in Figure 3) or gene function can be disrupted
by using viruses to introduce exogenous DNA sequences
in the zebrafish genome. Through a forward genetic approach,
Sun et al. (41) identified ten genes associated with cystic
pronephros phenotypes. Three of these genes were homologs
of genes encoding Chlamydomonas intraflagellar transport
components (ift57, ift81, and ift172), strengthening the
connection between cilia defects and cystic kidney disease.
Indeed, IFT81 and IFT172 are known to cause kidney
Figure 2. | Flow chart describing some of the considerations the researcher should make when deciding which model is the most
appropriate for the study.Other considerations, such as the availability of animal facilities, ethics in place, and laboratory expertise are equally
important in the decision process.
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phenotypes in human (42,43). Positional cloning to map the
induced mutation traditionally constituted a bottleneck in
the ENU mutagenesis pipeline, but improved annotation
of the zebrafish genome and a reduction in sequencing
costs now allow the use of whole-exome sequencing for
rapid identification of new candidate genes that cause
kidney phenotypes in zebrafish mutants (44).
Zebrafish has proven to be a powerful tool not only in
forward genetic screens but also to study gene function and
pathways associated with kidney disease (Table 3). Two
decades ago, due to the absence of tools to efficiently
generate knockout fish for the gene of interest, morpholino
antisense oligonucleotides became a popular instrument to
obtain rapid and cost effective transient gene knockdown
in zebrafish embryos. Morpholinos can be injected in the
zebrafish embryo at the one- to four-cell stage and, by
interfering with transcript processing or translation, cause
gene silencing without changing the genomic sequence
(Figure 3). Some discrepancies between the phenotype
of morphants and that of the corresponding mutants
in several disease models, including kidney disease (41),
raised concerns regarding the specificity of the effects
induced by morpholinos in zebrafish. However, it has
been demonstrated that phenomena such as genetic com-
pensation could explain these discrepancies (45). Provided
that control experiments are put in place to ensure the
specificity of the effects observed (46), the use of morpholinos
in zebrafish is still considered a valuable tool to study the
function of genes involved in human inherited disorders,
including kidney disease.
By combining the injection of morpholinos with the
injection of mRNA for the corresponding human wild-type
Figure3. | Schematicof forwardandreversegenetics inzebrafish. (Left) Forwardgenetics: theENU-treated founder (F0) is ageneticmosaicwith
mutated germline. Crossingwithwild-type fish generates an F1 progeny that is raised and outcrossedwith wild-type fish. Half of the F2 progeny
will be heterozygous for the ENU-induced mutation. Outcross with wild-type fish generates an F3 progeny that is 25% homozygous for the
ENU-induced mutation. F3 zebrafish embryos or larvae are screened for phenotypes of interest and sequenced to identify the mutated gene.
(Right) Reverse genetics: zebrafishembryosat theone- to four-cell stage canbe injectedwith amorpholinodirectedagainst the geneof interest to
induce post-transcriptional targeted gene knockdown. Phenotypes of morphant embryos or larvae can be analyzed to study gene function.
Alternatively, targeted gene knockout can be obtained by injecting zebrafish embryos at the one- to two-cell stagewith Cas9 (mRNAor protein)
and guideRNA(s) directed against the gene of interest. Cas9 causes a double-strand break that is repaired through nonhomologous end joining,
often resulting in indels that impair geneexpression and/or function. Resulting crispants (F0) canbe geneticmosaics. Phenotypeandgenotypeof
the F0 can be analyzed to study gene function. Alternatively, F0 crispants can be raised, genotyped, and the heterozygous founder is outcrossed
withwild-typefish togenerateanF1progeny thatwillbe50%heterozygous for theCas9-inducedmutation.F1fishare incrossed togenerateanF2
progeny that will be 25% homozygous for the mutation. The phenotype of F2 embryos, larvae, or adults (if viable) is analyzed to study gene
function. ENU, N-ethyl-N-nitrosourea.
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Table 3. Examples of zebrafish and mouse models that have differentially contributed to our understanding of the pathomechanisms of
human inherited kidney disease
Human Kidney Disease Zebrafish Mouse
Glomerulopathies
Alport syndrome The zebrafish mutant dragnet (alias col4a5) fails to
recapitulate the human phenotype. Loss of col4a5
expression leads to defects in the laminar
organization of the retinotectal projection, but no
glomerular phenotype is observable (126)
Col4a3 knockout mouse model of autosomal Alport
syndrome is characterized by progressive GN
with microhematuria and proteinuria, consistent
with thehumandisease, and focalmultilaminated
thickening and thinning of the glomerular
basement membrane starting at 4 wk. End stage
kidney failure happens at 14 wk with fibrotic
glomeruli and collapsed capillaries (57). The
finding that thesemice display anupregulation of
miR-21andthat inhibitionofmiR-21slowskidney
disease progression has identified a promising
therapeutic target (58)
Nephrotic syndrome
type 1 and 2
The functions of the podocyte-specific proteins
nephrin (nphs1) and podocin (nphs2) are highly
conserved between the zebrafish pronephros and
mammalian metanephros. Knockdown of nphs1
and nphs2 results in abnormal slit diaphragm and
foot process architecture and in altered
glomerular filtration (53)
Nphs12/2 andNphs22/2mice are born alive but die
within 24 h and 5 wk, respectively, indicating a
more severe phenotype when compared with
human (127). Nphs22/2 mice develop diffuse
mesangial sclerosis, indicating that, during
glomerulogenesis, absenceofpodocinmaylead to
important alterations in the podocyte-
endothelial-mesangial crosstalk (79)
Nephrotic syndrome
type 4
Knockdown of Wilms tumor 1a (wt1a) in zebrafish
embryos leads to defects in podocyte
development with effacement of foot processes,
abnormalities in the slit diaphragm, and
dysfunctional glomerular filtration, as assessed
by injected dextran clearance rate (47)
Wt1 null mice are embryonic lethal, showing failure
of kidney and gonad development. Metanephric
mesenchyme cells are apoptotic and the ureteric
bud does not stem from the Wolffian duct (128)
Tubulopathies/kidney ciliopathies
Autosomal dominant
tubulointerstitial
kidney disease–
UMOD
Uromodulin (umod) morphants do not display
kidney development defects, nor increased
susceptibility to nephrotoxins, nor significant
alterations in glomerular or tubule gene
expression (129), perhaps consistently with a lack
of a loop of Henle in the zebrafish
Umod null mice do not display anatomic or
functional kidney alterations, but have altered
levels of transporters in the loop of Henle (60)
Cystinosis Mutant ctns zebrafish exhibit cystine accumulation,
altered tubular reabsorption, and glomerular
permeability, in line with the human phenotype
(130)
Ctns2/2 mice on the 129Sv 3 C57BL/6 genetic
background, despite elevated kidney cystine
levels, do not show an overt kidney phenotype
(131), whereas Ctns2/2 on the C57BL/6
backgrounddevelophistologickidney lesionsbut
no clear glomerulopathy (78)
ADPKD Zebrafish embryos microinjected with mRNA,
encoding the C-terminal cytoplasmic portion of
polycystin-1, form pronephric and liver cysts at 3
d post-fertilization, demonstrating the
importanceofpkd1dosagetomaintainpronephric
and liver architecture in the zebrafish embryos
(132). pkd2 was found mutated in an insertional
mutagenic screen for zebrafish mutant embryos
that displayed cystic pronephros phenotypes (41)
Pkd1 and Pkd2 null mice are embryonic lethal,
whereas heterozygous mice are viable and
progressively developkidney cysts (62).Pkd2WS25
mice harbor an unstable allele. Localized absence
of polycystin-2 in Pkd2WS25 cyst-lining epithelia
implies a somatic loss of Pkd2 in kidney cysts (62)
and argues in favor of a two-hit hypothesis for
ADPKD pathogenicity; but the increased
proliferation in kidney noncystic, polycystin-2–
positive epithelia indicates that
haploinsufficiency of Pkd2 is sufficient to cause
cell proliferation in early polycystic kidney
disease (64). The conditional Pkd1cond/cond mouse
shows a variable onset of cystic kidney disease
which depends on the time of genetic inactivation
of Pkd1, indicating that the pathologic
consequences of inactivation depend on the
maturation status of the kidney (133)
Nephronophthisis
type 3
Knockdownofnphp3 in thezebrafish embryocauses
hydrocephalusandbodysymmetrydefectsdue to
ciliary abnormalities at theKupffer vesicle (134), a
temporary developmental organ of left-right axis
determination
Thepcymouse isanorthologofNPHP3andaslowly
progressive model of cystic kidney disease, with
kidney enlargement arising at 8wkand thickened
basement membrane (135). Pcy mice display a
significant increase in kidney cAMP
concentration and in the expression of V2R and
AQP2, which is a gene positively regulated by
cAMP (69)
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or mutant ortholog, it is possible to perform rescue exper-
iments to confirm the pathogenicity of novel mutations. For
instance, this kind of experiment in zebrafish was performed
to validate a novel missense mutation inWT1 (p.R458Q) as a
cause of familial FSGS (47).
Engineered endonucleases such as zinc-finger nucle-
ases, transcription activator-like effector nucleases, and the
CRISPR/Cas9 gene-editing system have now emerged as
tools for site-directed mutagenesis in zebrafish. In particular,
the versatility and high efficiency of CRISPR/Cas9 make it
the tool of choice in most laboratories for the rapid and
cost-effective generation of knockout fish lines (mating
scheme exemplified in Figure 3).
Several transgenic zebrafish lines that are useful in kidney
research are available. A transgenic line Tg(wt1b:EGFP), where
the sequence of the fluorescent protein GFP is downstream to
the Wilms tumor 1b promoter, can facilitate the identifica-
tion of the proximal part of the pronephros (48). Similarly,
the transgenic line Tg(cldnb:Lyn-GFP) (49,50) can facilitate
the visualization of the distal part of the pronephros and
the cloaca. The transgenic line Tg(bact:ARL13b-GFP), where
GFP is fused to the mouse ARL13B protein, can be useful
in the study of kidney ciliopathies, because it allows for
the visualization of the ciliary membrane (51). These
transgenic lines can be used to study functions of the
kidney gene of interest by microinjecting embryos with
morpholinos or by crossing them with mutant lines.
Moreover, they can be used in association with auto-
mated microscopy to analyze potential kidney effects
of a library of compounds in therapeutic or toxicology
drug screens (52).
Along with these powerful transgenic lines that allow
monitoring of kidney phenotypes, powerful functional
studies can be used to study kidney function, such as
filtration assays using a fluorescent dextran tracer, where
dextran is perfused into the vasculature and is used to
monitor glomerular filtration (47,53,54).
Limitations of the model include the fact that the zebrafish
has many duplicated genes due to a whole-genome dupli-
cation event in early teleost evolution (55), which can
complicate the generation of orthologous models for
human disease. A more specific issue for kidney research
is represented by the fact that a true ortholog of AQP2 is
lacking in the zebrafish, which makes it an unsuitable
model for the study of the genetic diseases affecting water
homeostasis (40,56).
Mouse Models of Inherited Kidney Disease:
the Gold Standard
The availability of tools to induce site-directed mutagen-
esis in the mouse using embryonic stem cells has histori-
cally established it as the most-used in vivo vertebrate model
organism for genetic-medicine research, well before the
advent of CRISPR/Cas gene-editing systems. The fact
that the mouse is a mammalian model and its small size
contribute to its popularity as a model organism.
Several landmark mouse models have contributed substan-
tially to the identification of pathomechanisms in kidney
disease (Table 3), one such example is Cosgrove et al.’s (57)
mouse model of Alport syndrome, characterized by pro-
gressive GNwithmicrohematuria and proteinuria, consistent
with the human disease. Studies on this mouse contributed to
the elucidation of the molecular alterations that characterize
the glomerular basement membrane in Alport syndrome
(57). Recently, miR-21, a small noncoding RNA, was shown
to be upregulated in this mouse and its inhibition
significantly slowed kidney disease progression (58).
Currently, anti–miR-21 (RG-012) is being evaluated in
human studies for Alport syndrome in a phase 2 clinical
trial (NCT02855268).
In regard to tubular disorders, there are many ortholo-
gous and nonorthologous models of tubulointerstitial and
cystic kidney disease.
Table 3. (Continued)
Human Kidney Disease Zebrafish Mouse
Nephronophthisis
type 6
Knockdown of cep290 in zebrafish embryos results
in retinal and brain defects as well as cyst
formation in the pronephros, resembling the
clinical features of patients with Joubert
syndrome (136). cep290 morphant fish exhibit
increased levels of gh2ax, a marker of DNA
damage response signaling, suggesting a role for
DNA damage or DNA damage response
signaling in the pathophysiology of CEP290-
associated kidney disease (137)
The Cep2902/2 mice on a 129/Ola background are
viable andpresent amild kidneyphenotype,with
collecting duct small kidney cysts but no
significant kidney enlargement, in line with a
NPHP phenotype. Abnormalities in ciliary
phenotype and in Hedgehog signaling are
observable in cystic epithelia (80).Cep2902/2mice
on a C57BL/6 background present severe
hydrocephalus and are lethal (80,138),
highlighting the possible contribution of genetic
modifiers in the definition of the phenotype
Nephronophthisis
type 9
Knockdown of nek8 in zebrafish embryos leads to
cyst formation and abnormal cardiac looping.
Similar phenotypes are observed when zebrafish
inversin (inv, orthologous of the genetic cause of
NPHP2) isknockeddown.Overexpressionofnek8
through mRNA microinjection rescues these
phenotypes in invmorphants, indicating thatnek8
may act downstream of inv (139)
The jckmousegenetically isanorthologousmodelof
NPHP9, with mutations in the Nek8 gene.
Phenotypically it resembles ADPKD, with
significantly enlarged kidneys at 4 wk. Kidneys
present high cAMP levels and elevated PCNA
staining in cyst-lining epithelia, revealing a
proliferative phenotype and promising
therapeutic targets (140–142)
ADPKD, autosomal dominant polycystic kidney disease; NPHP, nephronophthisis; V2R, vasopressin V2 receptor; AQP2, aquaporin-2;
PCNA, proliferating cell nuclear antigen.
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Mice with kidney-specific inactivation ofHNF1b develop
PKD and display downregulation of Umod, Pkhd1, and Pkd2
genes, showing that HNF1b is at the center of a transcrip-
tional network in kidney disease (59).
Umod null mice do not display anatomic or functional
kidney alterations in normal conditions but were shown to
have altered levels of transporters in the loop of Henle (60).
More recently, mouse experiments showed a significant
expression of uromodulin in the early part of mouse distal
connecting tubule, where it is critical for tubule function,
structure, and plasticity (61).
Some very elegant orthologous mouse models of ADPKD
have been studied to unravel the pathogenicity of this disease,
contributing to the formulation of the “two-hit hypothesis”
(62–64), which sees the formation of cysts as a result of a loss
of heterozygosity in PKDgenes in the tubular epithelium and to
the investigation of the role of cilium in cyst formation (65,66).
Importantly, the contribution of mouse models to the
clarification of the pathomechanisms involved in kidney
disease has also led to the identification of several prom-
ising therapeutic targets. In a few cases, compounds that
were shown to modulate such targets and to ameliorate
the kidney phenotype were then assessed for safety and
efficacy in human studies. One major example of a drug
now used in the treatment of inherited kidney disease
as a result of successful translation of preclinical research
findings in mouse is tolvaptan. Subsequent to the finding
that kidney cAMP levels and expression of aquaporin-2
and vasopressin V2 receptor (V2R) were increased in
Pkd22/tm1Som (67), an orthologous model of ADPKD, and in
other rodent models (68,69), the efficacy of V2R antag-
onists as modulators of the cystic phenotype was tested.
Tolvaptan, a V2R antagonist, was shown to ameliorate kidney
disease in PCK rats (70) and pcy mice (71). As a result of these
preclinical studies, a landmark trial using tolvaptan in patients
with ADPKD was published in 2012 and has signifi-
cantly altered the treatment landscape for patients with this
condition (72).
However, in terms of translatability of preclinical find-
ings to clinical practice, tolvaptan represents the exception
rather than the rule.
Concerns have been raised regarding the poor trans-
lational value of certain therapeutic conclusions drawn
from preclinical models, including the mouse, in several
research fields such as nephrology (73,74).
The use of nonorthologous mouse models and interspe-
cies differences in gene expression and development may
partially account for these discrepancies. Differences also
exist in the end points considered when testing the efficacy
of a treatment in mouse and human. Moreover, there is
often a discrepancy in the stage of the disease when the
treatment is administered, with mice often being treated
at relatively early stages of the disease and patients often
presenting with an established disease. Finally, in an attempt
to minimize variance in animal experiments, inbred mouse
strains are usually used in research. However, this genetic
homogeneity hardly represents the genetic variability of the
human population that is the prospective recipient of the
treatment being tested (75).
Genetic background strongly influences the phenotype
of inherited kidney disease in mouse; it has been shown
to modulate the kidney phenotype in mouse models of
Alport syndrome (76,77), cystinosis (78), nephrotic syndrome
(79), and cystic kidney disease (80,81).
This should be taken into account when modeling kidney
disease and can actually be used to gain information on
how genetic modifiers contribute to kidney phenotype
with important consequences on our understanding of
kidney genetics and underlying disease mechanisms
(76,81,82).
Mammalian Cellular Models: Growing
Kidneys in a Dish
Monolayer cell cultures are attractive models for inherited
kidney disease because they are cheap and easy to manip-
ulate for the dissection of molecular pathways implicated in
the disease and for the use in large high-throughput screens
(83,84). There are several, well characterized cell lines
commonly used in kidney research such as the mouse
inner medullary collecting duct cell line (mIMCD-3) and the
dog kidney cell line Madin–Darby canine kidney (MDCK).
Inherited kidney diseases are extremely heterogeneous
and the phenotype can be strongly modulated by genetic
background. Isolation and culture of primary cells from the
patient can provide a useful human, patient-specific model
of the disease that not only intrinsically possesses the
primary genetic lesion without the need for gene editing
but also conserves the genetic background information.
Skin biopsy is an easy and minimally invasive way to
obtain patient-specific fibroblasts that can be grown and
studied in culture. Patient-specific fibroblasts have proven
to be extremely useful to dissect the molecular patho-
mechanism of several inherited kidney diseases, such as
nephronophthisis and cystic kidney disease in patients
with Joubert syndrome (85,86). However, molecular pathways
involved in kidney disease may not be active in nonkidney
cells, highlighting the importance in studying certain
mutations in the disease-relevant tissue context.
Urine-derived renal epithelial cells represent in this
regard an extremely powerful, noninvasive source of
disease-relevant, patient-specific primary material for
kidney research. Kidney tubular epithelia are exposed
to continuous passage of filtrate and living cells from
these tubules are normally excreted daily within the urine.
These cells can be isolated and specifically cultured to support
proliferation of kidney epithelial cells (87).
It has recently been shown that urine-derived renal
epithelial cells can be extremely powerful in vitromodels to
dissect pathomechanism of kidney diseases such as neph-
ronophthisis (88) and Fabry disease (89). They can also be
used to validate variants of unknown significance in patients
with inherited kidney disease, as in the case of a synonymous
variant in the nephronophthisis-associated gene NPHP3 that
was shown to affect the gene splicing in a tissue-specific
manner (90). Moreover, they can be used to identify novel
therapeutic targets and test new therapies with a precision
medicine approach (80,88,91).
In vitro two-dimensional (2D) cell models are therefore
powerful models of kidney disease that are amenable to
personalized and high-throughput studies (Figure 4).
However, the human kidney is characterized by a highly
organized architecture and standard monolayer cultures
fail to recapitulate cell-cell and cell–extracellular matrix
CJASN 15: 855–872, June, 2020 Disease Modeling of Human Genetic Kidney Disorders, Molinari and Sayer 865
interactions, polarity, and three-dimensional (3D) tissue
structure of the kidney epithelium, which are particularly
relevant in the pathogenicity of tubular disorders (92,93). To
obtain more physiologically relevant 3D models to better
mimic the phenotypes observed in vivo, many cell types
traditionally used for 2D cell culture models of kidney
disease have been adapted to grow in 3D spheroidal
cellular aggregates. mIMDC-3, MDCK, and urine-derived
renal epithelial cell lines can be grown in Matrigel to form
luminated spheroids that mimic the polarized epithelial
structure of kidney tubules and have been extensively used
to study pathomechanisms of tubular disorders such as
nephronophthisis (80,94–97) (Figure 4).
Another characteristic of the kidney tissue relevant when
studying pathomechanisms of kidney disease is the co-
existence within the kidney of multiple cell types. Tran-
scriptomic analysis found evidences of crosstalk between
cell types (98,99), which is essential to guide gene expres-
sion for correct response to stimuli and tissue homeostasis.
Disturbance to this process can be extremely relevant for
kidney disease (99) and the study of such mechanisms
requires higher complexity systems.
Recent advances in stem cell research have led to new
protocols that allow generation of kidney organoids from
induced pluripotent stem cells (100–102). These organoids
are characterized by unprecedented complexity due to
the presence of segmented nephron and a rudimentary
vasculature (Figure 4). These systems hold great potential in
recapitulating kidney disease, as shown in a work focusing
on kidney organoids with biallelic truncating mutations in
PKD1 and PKD2, introduced with the CRISPR/Cas9 gene-
editing system. Remarkably, fluid-filled cysts arose from
tubular structures within PKD kidney organoids, albeit at
low frequency in adhesion culture conditions (103). Interest-
ingly, suspension culture of kidney organoids led to a tenfold
increase in cystogenesis of PKD organoids, indicating that
adherent cues and microenvironment may play a role in
cyst formation (104).
Kidney organoids can be useful models not only for
tubular disorders but also to study glomerulopathies.
It has been shown that glomeruli sieved from kidney
organoids display improved marker expression, polarity,
and glomerular basement membrane matrisome when
compared with podocyte 2D cultures; they are amenable
to toxicity drug screens and can be used to model
inherited glomerulopathies such as congenital nephrotic
syndrome (105).
Despite these encouraging results, pilot studies to evaluate
the ability of kidney organoids to mimic the phenotypic
features of kidney disease have so far given variable results
(103,104,106) and limitations such as reduced size and
vasculature, immaturity (100,107), and lack/underrep-
resentation of certain cell types (107) may limit their
utility as disease models. The introduction of environ-
mental cues, such as exposure to flow stimuli, was shown
to be essential for an enhanced vascularization and
maturation of kidney organoids (108) (Figure 4). Indeed,
growing kidney organoids under flow stimuli on milli-
fluidic chips promotes the formation of vascular net-
works with perfusable lumens (108). These advances,
Figure 4. | The implementation of cell models for the study of inherited kidney disease is leading to complex human models that
incorporate several featuresof thehumankidney tissue.Thehumankidney iscomposedofmultiple cell types (epithelial, interstitial, andendothelial
cells) that are able to crosscommunicate and are arranged in a defined, hierarchical, tri-dimensional structure. The nephron epithelium is exposed
to urine flowwhichmay generate environmental cues potentially important for tissue homeostasis. The development of complex cell models
holds the potential to reveal new pathophysiologic mechanisms of kidney disease.
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together with efforts made using mouse embryonic stem
cells to develop more anatomically realistic kidney
organoids (102,109), can ultimately lead to the genera-
tion of functionally and structurally accurate human
kidney models that have a urine drain.
Conclusions
Animal and cellular models are essential tools in the
study of genetic kidney diseases. Such models have sub-
stantially expanded our knowledge of the genes and the
pathways involved and have contributed to the identifi-
cation of novel therapeutic targets.
So far, to draw conclusions on disease mechanisms to be
ultimately applied to human, kidney and preclinical re-
search in general have relied on the use of multiple disease
models with complementary features that are summarized
in this review.
Although the ease of manipulation of in vitro cellular
models allows straightforward dissection of disease mo-
lecular mechanisms, the complexity of in vivo animal
models supports the study of multiple cell types and tissue
interactions in a pathophysiologic context. Mammalian cell
cultures and zebrafish, due to their scalability, are particularly
suitable for high-throughput studies such as forward genetics
and drug screens. Such studies can then be taken forward
in the translational pipeline, using the mouse for detailed
study of pathomechanisms, as well as to investigate
molecular mechanisms of action and pharmacokinetics
of novel therapies. However, interspecies differences and
the heterogeneity and the extremely low frequency of
certain kidney disorders prompt for the implementation
of more accurate and complex human patient–specific
disease models.
Kidney organoids derived from patient-specific induced
pluripotent stem cells—by combining in a single human
model system several desirable features such as ease of
manipulation, scalability (110,111), and a certain degree
of complexity and suitability for precision medicine ap-
proaches (106)—hold great potential for the study of the
pathomechanisms of kidney diseases. Improvements in mor-
phologic and functional maturation, vascularization, and
representation of ureteric epithelium within kidney organo-
ids will be likely required to make them a fully competent
tool for human disease modeling.
Several major questions in the nephrology field remain
unanswered, such as the exact pathogenic mechanisms
that lead to kidney fibrosis, kidney-cyst formation, and
diabetic nephropathy. The hope is that the implementa-
tion of these powerful human models will in future
significantly contribute to answer these questions while
perhaps fueling new discoveries in the field of kidney
regenerative medicine.
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